



### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.2392 mL	6.1961 mL	12.3922 mL
5 mM	0.2478 mL	1.2392 mL	2.4784 mL
10 mM	0.1239 mL	0.6196 mL	1.2392 mL
50 mM	0.0248 mL	0.1239 mL	0.2478 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Mark Noviski, et al. NX-5948, a Selective Degradar of BTK, Significantly Reduces Inflammation in a Model of Autoimmune Disease. 2021 Nurix Therapeutics, Inc.

Searle Emma, et al. Initial findings from a first-in-human Phase 1a/b trial of NX-5948, a selective Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies. Blood 142 (2023): 4473.

Liu Z, et al. An overview of PROTACs: a promising drug discovery paradigm. Mol Biomed. 2022 Dec 20;3(1):46.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481